Subdued Growth No Barrier To Nichirei Corporation's (TSE:2871) Price
Nichirei Corporation's (TSE:2871) price-to-earnings (or "P/E") ratio of 19.3x might make it look like a sell right now compared to the market in Japan, where around half of the companies have P/E ratios below 14x and even P/E's below 9x are quite common. However, the P/E might be high for a reason and it requires further investigation to determine if it's justified.
With earnings growth that's superior to most other companies of late, Nichirei has been doing relatively well. It seems that many are expecting the strong earnings performance to persist, which has raised the P/E. You'd really hope so, otherwise you're paying a pretty hefty price for no particular reason.
See our latest analysis for Nichirei
If you'd like to see what analysts are forecasting going forward, you should check out our free report on Nichirei.Does Growth Match The High P/E?
In order to justify its P/E ratio, Nichirei would need to produce impressive growth in excess of the market.
If we review the last year of earnings growth, the company posted a worthy increase of 15%. The latest three year period has also seen a 20% overall rise in EPS, aided somewhat by its short-term performance. Accordingly, shareholders would have probably been satisfied with the medium-term rates of earnings growth.
Looking ahead now, EPS is anticipated to climb by 8.8% per annum during the coming three years according to the six analysts following the company. With the market predicted to deliver 9.5% growth each year, the company is positioned for a comparable earnings result.
In light of this, it's curious that Nichirei's P/E sits above the majority of other companies. Apparently many investors in the company are more bullish than analysts indicate and aren't willing to let go of their stock right now. These shareholders may be setting themselves up for disappointment if the P/E falls to levels more in line with the growth outlook.
The Bottom Line On Nichirei's P/E
Generally, our preference is to limit the use of the price-to-earnings ratio to establishing what the market thinks about the overall health of a company.
Our examination of Nichirei's analyst forecasts revealed that its market-matching earnings outlook isn't impacting its high P/E as much as we would have predicted. When we see an average earnings outlook with market-like growth, we suspect the share price is at risk of declining, sending the high P/E lower. Unless these conditions improve, it's challenging to accept these prices as being reasonable.
Before you take the next step, you should know about the 1 warning sign for Nichirei that we have uncovered.
You might be able to find a better investment than Nichirei. If you want a selection of possible candidates, check out this free list of interesting companies that trade on a low P/E (but have proven they can grow earnings).
Valuation is complex, but we're here to simplify it.
Discover if Nichirei might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSE:2871
Nichirei
Through its subsidiaries, engages in the processed food, marine products, meat and poultry products, temperature-controlled logistics, real estate, and biosciences businesses in Japan and internationally.
Flawless balance sheet with proven track record and pays a dividend.